Trendlines Medical Singapore and K2 Global selected for SGD100 million start-up program

Editor’s note: News of this announcement also appeared on The Edge Singapore and The Straits Times.

SPRING SEEDS Capital taps Trendlines Medical Singapore and Ozi Amanat’s K2 Global to collaborate in its SGD100 million investment allocation for tech start-ups.

Trendlines Medical Singapore logo

Trendlines Medical Singapore will collaborate with Ozi Amanat’s Singapore-based venture capital firm K2 Global and has been appointed as one of the partners under the Startup SG Equity program, which is administered by SPRING SEEDS Capital (SSC), the investment arm of Spring Singapore.

In July 2017, SSC announced a SGD100 million investment allocation to groom start-ups and issued a call to the appointed partners to co-invest in the health and biomedical sciences and other fields.

Singapore VC Ozi Amanat

Prominent venture capitalist Ozi Amanat founded K2 Global in 2014. With more than SGD250 million in committed capital, Amanat and K2 Global are among Singapore’s largest venture investors.

Together, Trendlines Medical Singapore and K2 Global will invest in medical technology companies seeking Series A funding. Trendlines Medical Singapore CEO Eric Loh remarked, “The collaboration between Trendlines Medical Singapore and K2 Global leverages Trendlines’ experience and proven track record in identifying, incubating, and grooming medical technology companies while working closely with K2 Global to provide growth capital and support to help scale operations and facilitate global opportunities. This is an ideal relationship that will contribute substantial value to Singapore’s medical technology start-up ecosystem.”

Founder of K2 Global Ozi Amanat added, “As a venture capital firm, K2 Global has had great successes in harnessing the value of growth-stage companies. The partnership with Trendlines Medical Singapore combines the strength of our two companies and adds tremendous value to medical technology companies seeking continuous business nurturing while exposing themselves to the plethora of opportunities in global markets.”

K2 Global logoTrendlines Medical Singapore and K2 Global anticipate co-investing with SCC in more than 11 companies during the eight-year period of the partnership. Both Loh and Amanat consider the pipeline of deals originating from Trendlines Medical Singapore’s incubator, and other companies with a strong development focus in Singapore, as a rich environment for investment.

Chairman of Trendlines Medical Singapore Todd Dollinger added, “We are pleased to work together with SPRING SEEDS Capital in translating health care and biomedical technologies — through active incubation and follow-on financing — into growing companies that will improve the human condition. Our participation in the Startup SG Equity program broadens our ability to develop early-stage medical technology companies in Singapore. Our collaboration with K2 Global will further strengthen our successful efforts in raising funds from strategic investors to boost the value of our portfolio companies. We expect numerous successful investment outcomes in the coming years.”

Read our full announcement.

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize
Contrast